Memorial Sloan Kettering surgeons describe a phase II trial comparing agents administered through HIPEC for cancers of the appendix, colon, and rectum.
Gastrointestinal Oncology Service Chief Leonard Saltz talks about advances in the personalized treatment and cure of rectal cancer in this Grand Rounds presentation.
Medical oncologist Nancy Kemeny reviews evidence for HAI in extending survival and improving quality of life for patients with colorectal cancer and liver metastases.
At Memorial Sloan Kettering we treat more than 2,500 people annually for primary and recurrent colon, rectal, and anal cancer, and have expertise in a range of associated conditions, including appendiceal malignancies, intestinal carcinoid tumors, abdominal desmoid tumors, peritoneal surface malignancies, and rare sacral and retroperitoneal tumors. We also treat Crohn’s disease, ulcerative colitis, perianal Paget’s disease, and various benign anorectal conditions.
Our physicians are experts in minimally invasive procedures such as laparoscopy, robotics, and transendoscopic microsurgery, the use of highly precise radiation therapies, and the application of techniques to preserve sphincter, bladder, and sexual function. Through a team approach involving surgeons, medical oncologists, radiation oncologists, pathologists, and others, we ensure that each patient receives the benefit of outstanding comprehensive and compassionate care. Our extensive clinical trial and research endeavors complement the patient care program.